Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) is one of the common malignant tumors in the head and neck, characterized by high malignancy, rapid growth and metastasis, high invasive ability, and high mortality. In recent years, surgery combined with chemotherapy or radiotherapy remains the preferred clinical...
Gespeichert in:
Veröffentlicht in: | Journal of oncology 2023, Vol.2023, p.4616682-11 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 11 |
---|---|
container_issue | |
container_start_page | 4616682 |
container_title | Journal of oncology |
container_volume | 2023 |
creator | Lu, Ying Yang, Jinjin Zhu, Junwen Shu, Yao Zou, Xuan Ruan, Qiao Luo, Shuyuan Wang, Yong Wen, Jun |
description | Oral squamous cell carcinoma (OSCC) is one of the common malignant tumors in the head and neck, characterized by high malignancy, rapid growth and metastasis, high invasive ability, and high mortality. In recent years, surgery combined with chemotherapy or radiotherapy remains the preferred clinical treatment for OSCC, despite considerable advances in diagnostic and therapeutic techniques. Hence, new targeted therapy is urgently needed. Histone modification affects the function of massive cells through histone acetyltransferase and histone deacetylase. Accompanied by the progress of some diseases, especially tumors, these proteins often show abnormal functions, and by reversing these abnormalities with drugs or gene therapy, the cancer phenotype can even be restored to normal. As a result, they are potential drug targets. This article reviewed the role of the histone dynamic process of acetylation modifications and their associated active modifying enzymes in the pathogenesis and progress of OSCC. Moreover, we explored the value of histone acetylation modification as a potential therapeutic target and the new progress of related drugs in clinical treatment. |
doi_str_mv | 10.1155/2023/4616682 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3106038583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3104856279</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1952-516fd665766caa544867f94b4691e190c59a21a8bb89a509ae5a25fcd7b4db703</originalsourceid><addsrcrecordid>eNp90M1LwzAYBvAgipsfN89S8CLoXJImaXIcRZ0w2cF5Lm_TlGW0zda0yv57O1pFPHjKG_jx8PAgdEXwAyGcTymm4ZQJIoSkR2hMhIwmknF8_OseoTPvNxgLhpU4RaNQUUkp5WO0mmUfUGnjA1sFzdoEc-sbV5lgpk2zL6CxrgpeXWZzq_vP4JY1FMHbroXStT6ITVEEMdTaVq6EC3SSQ-HN5fCeo_enx1U8nyyWzy_xbDHRRHE64UTkmRA8EkIDcMakiHLFUiYUMURhzRVQAjJNpQKOFRgOlOc6i1KWpREOz9Ftn7ut3a41vklK63VXBSrTtUpCggUOJZdhR2_-0I1r66prd1BMckEj1an7XunaeV-bPNnWtoR6nxCcHNZODmsnw9odvx5C27Q02Q_-nrcDdz1Y2yqDT_t_3BdF-oTc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3104856279</pqid></control><display><type>article</type><title>Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma</title><source>PubMed Central Open Access</source><source>Wiley-Blackwell Open Access Titles</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Lu, Ying ; Yang, Jinjin ; Zhu, Junwen ; Shu, Yao ; Zou, Xuan ; Ruan, Qiao ; Luo, Shuyuan ; Wang, Yong ; Wen, Jun</creator><contributor>Feng, Zhi-En ; Zhi-En Feng</contributor><creatorcontrib>Lu, Ying ; Yang, Jinjin ; Zhu, Junwen ; Shu, Yao ; Zou, Xuan ; Ruan, Qiao ; Luo, Shuyuan ; Wang, Yong ; Wen, Jun ; Feng, Zhi-En ; Zhi-En Feng</creatorcontrib><description>Oral squamous cell carcinoma (OSCC) is one of the common malignant tumors in the head and neck, characterized by high malignancy, rapid growth and metastasis, high invasive ability, and high mortality. In recent years, surgery combined with chemotherapy or radiotherapy remains the preferred clinical treatment for OSCC, despite considerable advances in diagnostic and therapeutic techniques. Hence, new targeted therapy is urgently needed. Histone modification affects the function of massive cells through histone acetyltransferase and histone deacetylase. Accompanied by the progress of some diseases, especially tumors, these proteins often show abnormal functions, and by reversing these abnormalities with drugs or gene therapy, the cancer phenotype can even be restored to normal. As a result, they are potential drug targets. This article reviewed the role of the histone dynamic process of acetylation modifications and their associated active modifying enzymes in the pathogenesis and progress of OSCC. Moreover, we explored the value of histone acetylation modification as a potential therapeutic target and the new progress of related drugs in clinical treatment.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>EISSN: 1687-8469</identifier><identifier>DOI: 10.1155/2023/4616682</identifier><identifier>PMID: 39282225</identifier><language>eng</language><publisher>Egypt: Hindawi</publisher><subject>Cancer therapies ; Cell cycle ; Cell growth ; Chromatin ; DNA damage ; DNA methylation ; Enzymes ; Epigenetics ; Kinases ; Medical prognosis ; Metabolism ; Metabolites ; Metastasis ; Proteins ; Signal transduction ; Squamous cell carcinoma ; Tumorigenesis</subject><ispartof>Journal of oncology, 2023, Vol.2023, p.4616682-11</ispartof><rights>Copyright © 2023 Ying Lu et al.</rights><rights>Copyright © 2023 Ying Lu et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1952-516fd665766caa544867f94b4691e190c59a21a8bb89a509ae5a25fcd7b4db703</cites><orcidid>0000-0001-8989-1927 ; 0000-0002-0456-8862 ; 0000-0002-6437-0567</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39282225$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Feng, Zhi-En</contributor><contributor>Zhi-En Feng</contributor><creatorcontrib>Lu, Ying</creatorcontrib><creatorcontrib>Yang, Jinjin</creatorcontrib><creatorcontrib>Zhu, Junwen</creatorcontrib><creatorcontrib>Shu, Yao</creatorcontrib><creatorcontrib>Zou, Xuan</creatorcontrib><creatorcontrib>Ruan, Qiao</creatorcontrib><creatorcontrib>Luo, Shuyuan</creatorcontrib><creatorcontrib>Wang, Yong</creatorcontrib><creatorcontrib>Wen, Jun</creatorcontrib><title>Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma</title><title>Journal of oncology</title><addtitle>J Oncol</addtitle><description>Oral squamous cell carcinoma (OSCC) is one of the common malignant tumors in the head and neck, characterized by high malignancy, rapid growth and metastasis, high invasive ability, and high mortality. In recent years, surgery combined with chemotherapy or radiotherapy remains the preferred clinical treatment for OSCC, despite considerable advances in diagnostic and therapeutic techniques. Hence, new targeted therapy is urgently needed. Histone modification affects the function of massive cells through histone acetyltransferase and histone deacetylase. Accompanied by the progress of some diseases, especially tumors, these proteins often show abnormal functions, and by reversing these abnormalities with drugs or gene therapy, the cancer phenotype can even be restored to normal. As a result, they are potential drug targets. This article reviewed the role of the histone dynamic process of acetylation modifications and their associated active modifying enzymes in the pathogenesis and progress of OSCC. Moreover, we explored the value of histone acetylation modification as a potential therapeutic target and the new progress of related drugs in clinical treatment.</description><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Chromatin</subject><subject>DNA damage</subject><subject>DNA methylation</subject><subject>Enzymes</subject><subject>Epigenetics</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metastasis</subject><subject>Proteins</subject><subject>Signal transduction</subject><subject>Squamous cell carcinoma</subject><subject>Tumorigenesis</subject><issn>1687-8450</issn><issn>1687-8450</issn><issn>1687-8469</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp90M1LwzAYBvAgipsfN89S8CLoXJImaXIcRZ0w2cF5Lm_TlGW0zda0yv57O1pFPHjKG_jx8PAgdEXwAyGcTymm4ZQJIoSkR2hMhIwmknF8_OseoTPvNxgLhpU4RaNQUUkp5WO0mmUfUGnjA1sFzdoEc-sbV5lgpk2zL6CxrgpeXWZzq_vP4JY1FMHbroXStT6ITVEEMdTaVq6EC3SSQ-HN5fCeo_enx1U8nyyWzy_xbDHRRHE64UTkmRA8EkIDcMakiHLFUiYUMURhzRVQAjJNpQKOFRgOlOc6i1KWpREOz9Ftn7ut3a41vklK63VXBSrTtUpCggUOJZdhR2_-0I1r66prd1BMckEj1an7XunaeV-bPNnWtoR6nxCcHNZODmsnw9odvx5C27Q02Q_-nrcDdz1Y2yqDT_t_3BdF-oTc</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Lu, Ying</creator><creator>Yang, Jinjin</creator><creator>Zhu, Junwen</creator><creator>Shu, Yao</creator><creator>Zou, Xuan</creator><creator>Ruan, Qiao</creator><creator>Luo, Shuyuan</creator><creator>Wang, Yong</creator><creator>Wen, Jun</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8989-1927</orcidid><orcidid>https://orcid.org/0000-0002-0456-8862</orcidid><orcidid>https://orcid.org/0000-0002-6437-0567</orcidid></search><sort><creationdate>2023</creationdate><title>Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma</title><author>Lu, Ying ; Yang, Jinjin ; Zhu, Junwen ; Shu, Yao ; Zou, Xuan ; Ruan, Qiao ; Luo, Shuyuan ; Wang, Yong ; Wen, Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1952-516fd665766caa544867f94b4691e190c59a21a8bb89a509ae5a25fcd7b4db703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Chromatin</topic><topic>DNA damage</topic><topic>DNA methylation</topic><topic>Enzymes</topic><topic>Epigenetics</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metastasis</topic><topic>Proteins</topic><topic>Signal transduction</topic><topic>Squamous cell carcinoma</topic><topic>Tumorigenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Ying</creatorcontrib><creatorcontrib>Yang, Jinjin</creatorcontrib><creatorcontrib>Zhu, Junwen</creatorcontrib><creatorcontrib>Shu, Yao</creatorcontrib><creatorcontrib>Zou, Xuan</creatorcontrib><creatorcontrib>Ruan, Qiao</creatorcontrib><creatorcontrib>Luo, Shuyuan</creatorcontrib><creatorcontrib>Wang, Yong</creatorcontrib><creatorcontrib>Wen, Jun</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Ying</au><au>Yang, Jinjin</au><au>Zhu, Junwen</au><au>Shu, Yao</au><au>Zou, Xuan</au><au>Ruan, Qiao</au><au>Luo, Shuyuan</au><au>Wang, Yong</au><au>Wen, Jun</au><au>Feng, Zhi-En</au><au>Zhi-En Feng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma</atitle><jtitle>Journal of oncology</jtitle><addtitle>J Oncol</addtitle><date>2023</date><risdate>2023</risdate><volume>2023</volume><spage>4616682</spage><epage>11</epage><pages>4616682-11</pages><issn>1687-8450</issn><eissn>1687-8450</eissn><eissn>1687-8469</eissn><abstract>Oral squamous cell carcinoma (OSCC) is one of the common malignant tumors in the head and neck, characterized by high malignancy, rapid growth and metastasis, high invasive ability, and high mortality. In recent years, surgery combined with chemotherapy or radiotherapy remains the preferred clinical treatment for OSCC, despite considerable advances in diagnostic and therapeutic techniques. Hence, new targeted therapy is urgently needed. Histone modification affects the function of massive cells through histone acetyltransferase and histone deacetylase. Accompanied by the progress of some diseases, especially tumors, these proteins often show abnormal functions, and by reversing these abnormalities with drugs or gene therapy, the cancer phenotype can even be restored to normal. As a result, they are potential drug targets. This article reviewed the role of the histone dynamic process of acetylation modifications and their associated active modifying enzymes in the pathogenesis and progress of OSCC. Moreover, we explored the value of histone acetylation modification as a potential therapeutic target and the new progress of related drugs in clinical treatment.</abstract><cop>Egypt</cop><pub>Hindawi</pub><pmid>39282225</pmid><doi>10.1155/2023/4616682</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-8989-1927</orcidid><orcidid>https://orcid.org/0000-0002-0456-8862</orcidid><orcidid>https://orcid.org/0000-0002-6437-0567</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1687-8450 |
ispartof | Journal of oncology, 2023, Vol.2023, p.4616682-11 |
issn | 1687-8450 1687-8450 1687-8469 |
language | eng |
recordid | cdi_proquest_miscellaneous_3106038583 |
source | PubMed Central Open Access; Wiley-Blackwell Open Access Titles; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection |
subjects | Cancer therapies Cell cycle Cell growth Chromatin DNA damage DNA methylation Enzymes Epigenetics Kinases Medical prognosis Metabolism Metabolites Metastasis Proteins Signal transduction Squamous cell carcinoma Tumorigenesis |
title | Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A47%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Advances%20in%20the%20Histone%20Acetylation%20Modification%20in%20the%20Oral%20Squamous%20Cell%20Carcinoma&rft.jtitle=Journal%20of%20oncology&rft.au=Lu,%20Ying&rft.date=2023&rft.volume=2023&rft.spage=4616682&rft.epage=11&rft.pages=4616682-11&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2023/4616682&rft_dat=%3Cproquest_cross%3E3104856279%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3104856279&rft_id=info:pmid/39282225&rfr_iscdi=true |